Safety considerations in the psychopharmacology of pediatric bipolar disorder

Amanda Y. Sun, Steven Woods, Robert L Findling, Ekaterina Stepanova

Research output: Contribution to journalReview article

Abstract

Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and families in evaluating and selecting between treatment options. Areas covered: This review focuses on medications that, in our clinical experience, are commonly prescribed for youth with BPD and were evaluated in prospective clinical trials for the treatment of pediatric BPD. This paper highlights acute and long-term AEs described in these studies. Expert opinion: Most medications increase risk of AEs in youth with BPD. Treatment with lithium may lead to thyrotropin elevations, but generally does not cause significant weight gain. Divalproex may lead to weight gain; however, this finding was not consistent in comparison studies with lithium. Olanzapine, risperidone, quetiapine, and asenapine are associated with metabolic abnormalities and weight gain. Studies of ziprasidone, aripiprazole and lurasidone do not suggest significant metabolic AEs. More studies are needed to assess efficacy and safety of medications in managing pediatric BPD. Special focus on long-term maintenance trials is required to further identify long-term AEs in this population.

Original languageEnglish (US)
Pages (from-to)777-794
Number of pages18
JournalExpert Opinion on Drug Safety
Volume18
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Psychopharmacology
Bipolar Disorder
Pediatrics
Safety
Weight Gain
olanzapine
Lithium
Therapeutics
Risperidone
Expert Testimony
Valproic Acid
Thyrotropin
Clinical Trials
Pharmacology
Population

Keywords

  • adverse events
  • anticonvulsants
  • antipsychotics
  • bipolar disorder
  • lithium
  • pediatric
  • Safety
  • treatment

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety considerations in the psychopharmacology of pediatric bipolar disorder. / Sun, Amanda Y.; Woods, Steven; Findling, Robert L; Stepanova, Ekaterina.

In: Expert Opinion on Drug Safety, Vol. 18, No. 9, 01.01.2019, p. 777-794.

Research output: Contribution to journalReview article

@article{172b8fff69c74a8ab1626a9669d6292c,
title = "Safety considerations in the psychopharmacology of pediatric bipolar disorder",
abstract = "Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and families in evaluating and selecting between treatment options. Areas covered: This review focuses on medications that, in our clinical experience, are commonly prescribed for youth with BPD and were evaluated in prospective clinical trials for the treatment of pediatric BPD. This paper highlights acute and long-term AEs described in these studies. Expert opinion: Most medications increase risk of AEs in youth with BPD. Treatment with lithium may lead to thyrotropin elevations, but generally does not cause significant weight gain. Divalproex may lead to weight gain; however, this finding was not consistent in comparison studies with lithium. Olanzapine, risperidone, quetiapine, and asenapine are associated with metabolic abnormalities and weight gain. Studies of ziprasidone, aripiprazole and lurasidone do not suggest significant metabolic AEs. More studies are needed to assess efficacy and safety of medications in managing pediatric BPD. Special focus on long-term maintenance trials is required to further identify long-term AEs in this population.",
keywords = "adverse events, anticonvulsants, antipsychotics, bipolar disorder, lithium, pediatric, Safety, treatment",
author = "Sun, {Amanda Y.} and Steven Woods and Findling, {Robert L} and Ekaterina Stepanova",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14740338.2019.1637416",
language = "English (US)",
volume = "18",
pages = "777--794",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Safety considerations in the psychopharmacology of pediatric bipolar disorder

AU - Sun, Amanda Y.

AU - Woods, Steven

AU - Findling, Robert L

AU - Stepanova, Ekaterina

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and families in evaluating and selecting between treatment options. Areas covered: This review focuses on medications that, in our clinical experience, are commonly prescribed for youth with BPD and were evaluated in prospective clinical trials for the treatment of pediatric BPD. This paper highlights acute and long-term AEs described in these studies. Expert opinion: Most medications increase risk of AEs in youth with BPD. Treatment with lithium may lead to thyrotropin elevations, but generally does not cause significant weight gain. Divalproex may lead to weight gain; however, this finding was not consistent in comparison studies with lithium. Olanzapine, risperidone, quetiapine, and asenapine are associated with metabolic abnormalities and weight gain. Studies of ziprasidone, aripiprazole and lurasidone do not suggest significant metabolic AEs. More studies are needed to assess efficacy and safety of medications in managing pediatric BPD. Special focus on long-term maintenance trials is required to further identify long-term AEs in this population.

AB - Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and families in evaluating and selecting between treatment options. Areas covered: This review focuses on medications that, in our clinical experience, are commonly prescribed for youth with BPD and were evaluated in prospective clinical trials for the treatment of pediatric BPD. This paper highlights acute and long-term AEs described in these studies. Expert opinion: Most medications increase risk of AEs in youth with BPD. Treatment with lithium may lead to thyrotropin elevations, but generally does not cause significant weight gain. Divalproex may lead to weight gain; however, this finding was not consistent in comparison studies with lithium. Olanzapine, risperidone, quetiapine, and asenapine are associated with metabolic abnormalities and weight gain. Studies of ziprasidone, aripiprazole and lurasidone do not suggest significant metabolic AEs. More studies are needed to assess efficacy and safety of medications in managing pediatric BPD. Special focus on long-term maintenance trials is required to further identify long-term AEs in this population.

KW - adverse events

KW - anticonvulsants

KW - antipsychotics

KW - bipolar disorder

KW - lithium

KW - pediatric

KW - Safety

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85070958024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070958024&partnerID=8YFLogxK

U2 - 10.1080/14740338.2019.1637416

DO - 10.1080/14740338.2019.1637416

M3 - Review article

C2 - 31242784

AN - SCOPUS:85070958024

VL - 18

SP - 777

EP - 794

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 9

ER -